Citations

Clear

330 citation(s) found for "Weber, J".

EZH2 controls microRNA expression in T cells in atherosclerosis
Li, X, Bonfiglio, C, Lacy, M, Peano, C, Cassanmagnago, G, Weber, C, Lutgens, E Esther, Santovito, D, Atzler, D, Bonfiglio, Cecilia Assunta , Lacy, Michael , Peano, Clelia , Weber, Christian , Lutgens, Esther , Santovito, Donato , Atzler, Dorothee

Mayo Clinic

Cardiovascular Research | May 14, 2026 | Volume: 122 | Issue: Supplement_1 | Pages: No page available

10.1093/cvr/cvag092.018 Get It

Abstract Background T cell activation and polarization drive atherosclerosis. Among the mediators underlying T cell polarization, the epigenetic enzyme EZH2 catalyses the repressive mark H3K27me3. In humans, EZH2 is upregulated in T cells in advanced atherosclerosis, whereas its deficiency in T cells in mice limits plaque formation via an anti-inflammatory response. Emerging evidence indicates that EZH2 can also regulate lncRNAs and miRNAs by depositing H3K27me3 at their loci, repressing transcription. Purpose We hypothesize that EZH2 governs lncRNAs and miRNAs expression in T cells in the context of atherogenesis. Methods CD4+ T cells were isolated from spleens of atherosclerosis-prone T cell-specific Ezh2 (Ezh2cd4)-KO mice and WT littermates. Small RNA-seq (SMARTer® smRNA-Seq) and transcriptomic profiling (Prime-seq) were performed. Differential expression was assessed using edgeR. Selected miRNAs were validated by RT-qPCR. Putative miRNA targets were retrieved from miRTarBase (v. 8) and TargetScan, and gene ontology enrichment was performed using Metascape. Results In CD4+ T cells from Ezh2cd4-KO mice, 41 out of 2,950 mature miRNAs were differentially expressed (log2FC > |0.8|, FDR < 0.05), with 27 upregulated and 14 downregulated. Top upregulated miRNAs included miR-125a-5p, miR-130a-3p, miR-744-5p, miR-181a-5p, miR-181b-5p, miR-374b-5p, miR-99b, miR-3085, and miR-7049-3p. RT-qPCR confirmed that expression of miR-125a-5p, miR-181a-5p, miR-181b-5p, and miR-99b-5p were upregulated in Ezh2-deficient murine CD4+ T cells. GO enrichment analysis of downregulated genes revealed enrichment of IL-4, IL-9, IL-10, and TGF-β pathways, suggesting their relevance in T-cell function and differentiation. In human Jurkat T cells, pharmacological EZH2 inhibition using GSK126 or tazemetostat resulted only in the upregulation of miR-125a-5p and miR-99b-5p, confirming the conservation of the mechanisms in humans. Integration of our Prime-seq transcriptomics and smallRNAseq datasets with human and mouse predicted and experimentally validated targets of miR-125a-5p and miR-99b-5p identified six conserved target genes: STAT1, FAM169B, NDRG3, PSMB9, TRIB1, and RAB3IP. Conclusions Our findings indicate that Ezh2 represses miRNA expression in T cells during atherogenesis, thereby possibly promoting differentiation toward pro-atherogenic subsets while restraining anti-atherogenic transcriptional programs. Further research is needed to elucidate the underlying mechanisms. Ezh2-regulated miRNAs may represent promising targets to direct T cell plasticity to combat atherosclerosis.
Mindfulness Interventions for Adolescents With Chronic Pain: A Systematic Review and Meta‐Analysis
Harbeck‐Weber, Cynthia , Murad, Sammy T., Ramachandran, Neha , Sim, Leslie a., Weiss, Karen, Gerberi, Dani, Murad, M. Hassan, Saadi, Samer, Saadi, Samer , Harbeck‐Weber, Cynthia , Saadi, Samer , Murad, Sammy T., Sim, Leslie , Gerberi, Dana

Mayo Clinic

European Journal of Pain | May 7, 2026 | Volume: 30 | Issue: 5 | Pages: No page available

10.1002/ejp.70274 | PMID 42093121 Get It

ABSTRACT Background and Objective Despite growing interest in mindfulness‐based interventions for adolescents with chronic pain, the data have not been systematically summarized. We conducted a systematic review and meta‐analyses to estimate the effect of mindfulness‐based interventions on pain intensity, catastrophizing, acceptance and interference; functioning, quality of life, and anxiety and depression in youth with chronic pain. Databases and Data Treatment Electronic databases CINAHL, CCTR, Embase, Medline, PsycINFO, Scopus and Web of Science were systematically searched to January 2, 2025. Studies were included if they were in English, included > 5 patients, were not part of intensive interdisciplinary pain treatment and included pre‐post outcomes from mindfulness‐based interventions delivered to adolescents with chronic pain. Risk of bias was assessed with the Newcastle–Ottawa Scale. Results Fourteen studies including a total of 323 adolescents were identified. There were significant within group improvements in pain intensity, pain catastrophizing, pain acceptance, pain interference, functioning, depression, anxiety, and quality of life, with results maintained or increased at follow‐up effect sizes at follow‐up were moderate to large (e.g., quality of life SMD = 0.33; pain intensity SMD = −0.73; pain interference SMD = −1.44). Heterogeneity of results was generally moderate to high. Compared to standardized long interventions, variable length interventions showed greater pre‐post changes in functioning, pain intensity, and pain catastrophizing. The certainty in the estimates was generally low, due to risk of bias and pre‐post designs. Conclusions Although adolescents with chronic pain report improvements after participating in mindfulness‐based interventions, rigorous RCTs are needed to substantiate these results. Significance Statement Chronic pain in youth is common and difficult to treat. Previous interventions have largely been based on cognitive‐behavioural therapy and not successful for all. This is the first systematic review and meta‐analysis in paediatric chronic pain to focus on mindfulness‐based interventions, highlighting an alternative and potentially effective intervention approach. This study informs clinicians about an effective intervention approach and assists researchers in identifying gaps for further research.
Update from the Long-Term Follow-Up Phase of ReNeu: A Pivotal Phase 2b Trial of Mirdametinib in Adults and Children with Neurofibromatosis Type 1-Associated Symptomatic Plexiform Neurofibroma
Hirbe, A., Shuhaiber, H., Viskochil, D., Sidhu, A., Meade, J., Weintraub, L., Langseth, A., Weber, M., Lokku, A., Hajjar, F., Antony, R., Schiff, D., Raslan, A., Nevel, K., Babovic-Vuksanovic, D., Gershon, T., Hirbe, Angela C. , Shuhaiber, Hans, Viskochil, David , Sidhu, A., Langseth, Abraham J. , Lokku, Armend, Hajjar, Fouad, Babovic‐Vuksanovic, Dusica , Gershon, Timothy R.

Mayo Clinic

Neuropediatrics | April 27, 2026 | Volume: 57 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1822861 Get It

Addressing Skin Adverse Events during Mirdametinib Treatment in Patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas: Guidance from Experts on the Management of MEK Inhibitor-Associated Skin AEs
Hirbe, A., Anadkat, M., Boull, C., Nickerson, M., Weber, M., Babovic-Vuksanovic, D., Gershon, T., Hirbe, Angela C. , Anadkat, Milan J. , Boull, Christina , Babovic‐Vuksanovic, Dusica , Gershon, Timothy R.

Mayo Clinic

Neuropediatrics | April 27, 2026 | Volume: 57 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1822860 Get It

Evaluation of standard and modified two-tiered testing algorithms using well-characterized early Lyme disease samples
Horn, Elizabeth J. , Menefee, Barry, Schotthoefer, Anna M. , Dempsey, George, McArdle, Matt, Weber, A., Luca, Cathy De, Pritt, Bobbi S. , Branda, John A. , Horn, Elizabeth J , Weber, Allison F , Pritt, Bobbi S , Dempsey, George, McArdle, Matthew

Mayo Clinic

Journal of Clinical Microbiology | April 21, 2026 | Volume: 64 | Issue: 5 | Pages: No page available

10.1128/jcm.01187-25 | PMID 42012197 Get It

ABSTRACT Current laboratory testing for Lyme disease (LD) relies on serology. We evaluated the performance of standard two-tiered testing (STTT) and modified two-tiered testing (MTTT) algorithms using samples obtained from well-characterized patients with early LD in the U.S. East Coast and Upper Midwest. Participants with signs and symptoms of early LD (cases) and controls were enrolled by Lyme Disease Biobank. We compared the performance of four FDA-cleared STTT or MTTT algorithms using serum samples from 251 participants (107 cases, 69 with a convalescent draw; 144 endemic controls). At the initial blood draw, algorithm sensitivity ranged from 22% to 36%, with specificity ranging from 98% to 100%. MTTT algorithms showed higher sensitivity compared with STTT algorithms ( P ≤ 0.05). One STTT algorithm was less sensitive than the other ( P = 0.035), and there was no significant difference in sensitivity between MTTT algorithms. There was also discordance between algorithms; only 22 of the 45 samples classified as laboratory confirmed by Lyme Disease Biobank testing were positive using all algorithms evaluated. Likelihood of positive two-tiered serology among cases with a suspected erythema migrans (EM) skin lesion increased with longer lesion duration and/or when presenting with >1 constitutional symptom. Participants with suspected EM without constitutional symptoms were unlikely to test positive by any algorithm evaluated. Testing convalescent samples did not improve LD detection, and seroconversion was rare. While MTTT confirmed more early LD cases than STTT, all two-tiered algorithms evaluated were insensitive in this population. Novel diagnostics that improve laboratory confirmation for early LD are urgently needed. IMPORTANCE This study confirms that two-tiered serologic testing algorithms are insensitive in early Lyme disease, particularly within the first 2 weeks after symptom onset or when erythema migrans is not accompanied by constitutional symptoms. It also demonstrates that seroconversion is rare after antibiotic treatment. These results highlight the need for novel diagnostics for early Lyme disease that do not rely on serologic testing.
Operative Strategies and Wound Complications for Morel-Lavallee Injuries Undergoing Excisional Debridement: A Pacific Coast Surgical Association Multicenter Study
Nguyen, Peter , Grigorian, Areg , Costantini, Todd, Santorelli, Jarrett, Husen, Lilian Von, Inaba, Kenji, Schellenberg, Morgan, Stephens, Daniel, Chaar, Mohamad Abou, Mahmoud, Khalid, Schreiber, Martin, Minoza, Karen, Underwood, Samantha, Biffl, Walter, Lü, Ning , Bayat, Dunya, Edwards, Sara, Tillou, Areti, Zheng, Dennis J. , Plevin, Rebecca E. , Stein, Deborah, Smith, Juliana, Sonntag, Cheyenne C., Callcut, Rachael A. , Furlong, Harly, Graeff, Leonardo Weber, Trevizo, Eric, Cochran-Yu, Meghan, Duncan, Thomas, Diaz, Graal , Neville, Angela , Balan, Naveen , Siletz, Anaar, Ley, Eric, Park, Greigory, Alexander, Juliet, Johnson, Arianne, Cotton-Betteridge, Aaron , Smith, Maren, Alvarez, Claudia, Scolaro, John, Aryan, Negaar , Nahmias, Jeffry, Nguyen, Peter D , Abou Chaar, Mohamad , Lu, Ning , Coimbra, Raul , Balan, Naveen , Alvarez, Claudia , Aryan, Negaar , Costantini, Todd W. , Dilday, Joshua C. , Inaba, Kenji , Schellenberg, Morgan A. , Stephens, Daniel, Chaar, Mohamad K. Abou , Minoza, Karen , Biffl, Walter L. , Tillou, Areti , Kim, Hannah , Graeff, Leonardo W., Duncan, Thomas K. , Kim, Dennis S. , Siletz, Anaar E., Ley, Eric J. , Scolaro, John A. , Nahmias, Jeffry T.

Mayo Clinic

The American Surgeon™ | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261443695 | PMID 41990323 Get It

Morel-Lavallee lesions (MLLs) are traumatic closed degloving injuries with operative intervention (OI), especially excisional debridement, remaining the mainstay of treatment. However, high-quality evidence describing operative techniques and outcomes remains limited. This study aimed to characterize current OI practices and associated outcomes, especially among patients undergoing excisional debridement, hypothesizing an increased risk of wound complications with this approach for MLLs. Methods This prospective (2021-2024), multicenter, observational study was conducted across 15 trauma centers and included patients diagnosed with MLL who underwent OI. The association between operative technique (eg, excisional debridement) and the primary outcome of wound complications was evaluated. Wound complications were defined as cellulitis, deep wound infection, skin necrosis, necrotizing soft tissue infection (NSTI), and/or organized hematoma. Results Of 88 MLL patients undergoing OI, 36 (40.9%) had excisional debridement, with 4 (11.1%) limited excision to skin, 20 (55.6%) extended to subcutaneous tissue, and 12 (33.3%) down to muscle. Excisional debridement had higher rates of skin necrosis (22.2% vs. 1.9%, P = .002). Although overall rates of wound complications were statistically similar between cohorts (33.3% vs. 17.3%, P = .098), univariate analysis demonstrated excisional debridement had increased risk of wound complications (OR 2.52, CI 1.07-5.97, P = .035). Conclusion This prospective multicenter study over three years demonstrated that a fifth of MLLs undergoing excisional debridement developed postoperative skin necrosis. Excisional debridement also had a more than two-fold increased risk of wound complications compared to other OIs. These findings underscore the importance of investigating alternative operative techniques, such as incision and drainage or minimally invasive debridement methods.
Mechanical dyssynchrony and septal–lateral perfusion heterogeneity predict adverse left ventricular remodelling beyond ECG-defined LBBB
Brandão, Simone Cristina Soares, Joseph, Lee , Brown, Jenifer M. , Lopez, Diana, Lemley, M A R K, Ramirez, Giselle, Kavanagh, P A U L, Kriekinge, Serge D. Van , Builoff, Valerie , Divakaran, Sanjay, Weber, Brittany, Hainer, Jon, Carre, Sylvain , Blankstein, Ron, Dorbala, Sharmila, Le, Viet T, Mason, Steve, Chareonthaitawee, Panithaya, Wopperer, Samuel, Rosamond, Thomas, Berman, D., Dey, Damini, Carli, Marcelo F Di, Slomka, Piotr J, Huck, Daniel M, Soares Brandão, Simone Cristina , Kavanagh, Paul , Divakaran, Sanjay , Weber, Brittany , Hainer, Jon , Blankstein, Ron , Dey, Damini , Di Carli, Marcelo F , Huck, Daniel , Brown, Jenifer Michelle , Lopez, Diana, Lemley, Mark , Kavanagh, Paul , Liang, Joanna, Dorbala, Sharmila , Le, Viet T. , Mason, Steve, Knight, Stacey , Chareonthaitawee, Panithaya , Wopperer, Samuel, Berman, Daniel S. , Dey, Damini , Carli, Marcelo F. Di , Slomka, Piotr J

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | March 26, 2026 | Volume: 27 | Issue: 6 | Pages: 1255-1265

10.1093/ehjci/jeag081 | PMID 41902398 Get It

Abstract Aims Left bundle branch block (LBBB) is associated with mechanical dyssynchrony, heterogeneous perfusion, and adverse left ventricular (LV) remodelling. However, not all patients with LBBB develop cardiomyopathy, and dyssynchrony can occur without conduction defects. The role of microvascular dysfunction remains uncertain. We aimed to assess how mechanical dyssynchrony and perfusion heterogeneity relate to LV remodelling and function in patients with and without LBBB. Methods and results We analysed 233 patients with LBBB and 932 matched controls who underwent PET myocardial perfusion imaging, assessing mechanical dyssynchrony (phase entropy), LV volumes, and ejection fraction (EF); coronary vascular resistance (CVR), myocardial blood flow (MBF), myocardial flow reserve (MFR) as markers of microvascular function; and septal-to-lateral MBF ratio (SLR) as a measure of regional perfusion heterogeneity. Compared with controls, LBBB patients had greater dyssynchrony (56% vs. 40%), larger LV volumes, and lower EF (54% vs. 67%) (all P < 0.001), as well as higher stress CVR (37 vs. 34 mmHg/mL·min−1·g−1), and lower MBF (2.4 vs. 2.6 mL/min/g), MFR (2.4 vs. 2.6), and SLR (0.95 vs. 1.00) (all P < 0.05). Among patients with dyssynchrony, SLR <1.0 identified greater remodelling. In multivariable regression, phase entropy and SLR independently predicted LV volumes and EF, with adverse effects of SLR reduction amplified in LBBB (interaction P < 0.01). In Cox analysis, phase entropy (HR:1.02, P = 0.01), MFR (HR:0.62, P < 0.001), and LVEF (HR:0.97, P < 0.001) were independently associated with death or heart failure hospitalization, whereas LBBB was not. Conclusion Mechanical dyssynchrony and perfusion heterogeneity independently predict adverse LV remodelling, irrespective of LBBB. Integrated imaging improves cardiomyopathy stratification.
Vertebral metastatic disease: A paradigm shift
Nguyen, Annee , Trivedi, Trupti, O’Callaghan, Ellen, Yoo, Seeley , Ahmed, Ramzy , Ramos, Rafael De La Garza, Charest-Morin, Raphaële , Sciubba, Daniel, Shin, John H, Laufer, I., Barzilai, Ori, Gokaslan, Z., Sahgal, Arjun, Weber, Michael, Sullivan, Patricia L. Zadnik, Dea, Nicolas, Mullikin, Trey C. , Goodwin, C Rory, Goodwin, C. Rory , Clarke, Michelle, Dea, Nicolas , Goodwin, C Rory , Trivedi, Trupti , O’Callaghan, Ellen , Zachem, Tanner J. , Ramos, Rafael De la Garza , Bilsky, Mark H. , Sciubba, Daniel M. , Clarke, Michelle J. , Tatsui, Claudio Esteves , Laufer, Ilya , Barzilai, Ori , Gokaslan, Ziya L., Sahgal, Arjun , Dea, Nicolas , Lazáry, Áron

Mayo Clinic

Neuro-Oncology Advances | March 20, 2026 | Volume: 8 | Issue: Supplement_3 | Pages: iii21-iii36

10.1093/noajnl/vdag011 | PMID 42221982 Get It

Abstract Vertebral metastatic disease results from many types of cancer and can have a devastating impact on patient mobility, psychological health, quality of life, and ultimately overall patient survival. However, the development of radiotherapy and surgical techniques has rapidly surged in conjunction with ongoing advances in basic science and translational studies. In this review, we discuss the paradigm shift in our understanding of the epidemiology and treatment algorithms for spinal oncology, ranging from preoperative optimization strategies, radiation and surgical techniques, the utilization of molecular markers and targeted therapeutics in medical oncology, and prognostication tools that underscore a new multidisciplinary approach to spinal oncology care.
Alzheimer's disease Stage 1 and 2: Biology, diagnostics, and treatment
Schindler, Suzanne E., Arias, Jalayne J., Beasley, Brent W. , Farrar, Gill , Fowler, Nicole R., Jack, Clifford R., Jönsson, Linus, Joyce, Geoffrey , Lansdall, Claire J., Maruff, Paul, Mattsson‐Carlgren, Niklas, Mummery, Catherine J. , Murphy, Jennifer, Okhravi, Hamid , Petersen, Ronald C., Raman, Rema, Randolph, Christopher , Sass, Marie Reeberg , Reiman, Eric M., Salvadó, Gemma, Schöll, Michael, Siemers, Eric , Sperling, Reisa A., Thornton‐Wells, Tricia, Tortelli, Rosanna , Tosun, Duygu, Vandevrede, Lawren, Weninger, Stacie, Wessels, Alette M. , Zhou, Jin, Carrillo, Marı́a C., Weber, Christopher J., Carrillo, María C. , Jönsson, Linus , Schindler, Suzanne E. , Hansson, Oskar , Algeciras‐Schimnich, Alicia , Arias, Jalayne J. , Fowler, Nicole R. , Hartz, Sarah M. , Jack, Clifford R. , Maruff, Paul , Mattsson, Niklas , Murphy, Jennifer, Petersen, Ronald C. , Raman, Rema , Reiman, Eric M. , Salvadó, Gemma , Sperling, Reisa Anne , Thornton‐Wells, Tricia A., VandeVrede, Lawren , Villain, Nicolas , Zhou, Jin

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | March 12, 2026 | Volume: 12 | Issue: 1 | Pages: No page available

10.1002/trc2.70216 Get It

Abstract Advances in biomarker technology, digital cognitive assessments, and amyloid‐targeting therapies have redefined the opportunities for accurate and early diagnosis and care of Alzheimer's disease (AD). These advances also create new possibilities for intervention before the onset of cognitive impairment. This paradigm shift has increased the focus on Stages 1 and 2 of AD, in which individuals are cognitively unimpaired but exhibit biological evidence of disease. While early identification of AD offers an opportunity to intervene early to delay progression and preserve quality of life, it also presents complex challenges related to communicating diagnostic results to patients and their families, contextualizing the cost effectiveness of early diagnosis and treatment, and implementation of and equitable access to treatments. Recent, successfully enrolled, preclinical AD trials highlight the complex strategies required to identify asymptomatic, biomarker‐positive individuals on a large scale, and demonstrate critical knowledge gaps in inclusion, follow‐up, and long‐term outcome measurement. The Spring 2025 Alzheimer's Association Research Roundtable (AARR) meeting brought together academics, clinicians, industry, and regulatory leaders to exchange perspectives on current challenges, key learnings, and potential strategies for identifying and treating individuals in very early stages of AD, effectively and safely. This paper presents key takeaways from the Spring 2025 AARR meeting. Highlights New criteria for Alzheimer's disease (AD) enable early identification of AD pathology. Blood tests and digital cognitive assessment tools may facilitate early and personalized care. Plasma biomarkers may be scalable in clinical settings but need confirmation or follow‐up assessments in those individuals with equivocal results. Early therapy shows best results in people with lower initial amyloid and tau burden.
Minimally invasive myocardial infarction model recapitulates patient immune responses and reveals a pathogenic role for immature neutrophils
Möller-Ramon, Zoe , Kaltenbach, Anna Christina, Puhl, Sarah‐Lena , Kwok, Immanuel , Sicklinger, Florian, Jansen, Yvonne , Ernst, Annick, Nitz, Katrin , Schloss, Maximilian J. , Leuschner, Florian , Chan, Mark Yan Yee , Weber, Christian, Nitz, Katrin , Kaltenbach, Anna Cristina , Sicklinger, Florian , Weber, Christian , Steffens, Sabine , Duchêne, Johan

Mayo Clinic

No container title available | March 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.05.709757 Get It

Abstract Myocardial infarction (MI) triggers a systemic neutrophil response, yet the roles of distinct neutrophil subsets in cardiac remodeling remain unclear. Studying this requires murine models that accurately mirror human neutrophil dynamics. Here, we show that a minimally invasive intact-chest MI model is more pathophysiologically relevant than the standard open-chest approach for investigating post-MI immune responses. In the open-chest model, surgical trauma disrupts bone marrow homeostasis, releases large numbers of immature neutrophils, and masks MI-specific immune mechanisms. In contrast, the intact-chest model preserves bone marrow integrity and induces only a modest rise in circulating immature neutrophils, closely reflecting MI patient profiles. We further demonstrate that accumulation of immature neutrophils in the infarcted heart exacerbates cardiac dysfunction. Beyond neutrophils, the overall cardiac immune landscape differs markedly between both models. Collectively, our findings establish the intact-chest model as superior for studying post-MI inflammation and reveal immature neutrophils as mediators of adverse cardiac remodeling.